Company intelligence / Profile preview

Clover Leaf

New Haven, Connecticut, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Cloverleaf Bio is developing engineered tRNA therapeutics for oncology with a platform capable of directly inhibiting up to 25 cancer-associated enzymes per molecule. As of October 2025, all evidence indicates pre-clinical development and no clinical trial results published[1][3][4].

Therapeutic areas: Oncology
Modalities: RNA therapyEngineered tRNA therapeutic
Industry: Biotech

Partnerships

Mission BioCapital (seed funding and acceleration support)[3]

Beyond the preview

Go deeper on Clover Leaf.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clover Leaf.

Explore the full profile